PureTech Health (LON:PRTC) Stock Price Up 0.7% – Time to Buy?

PureTech Health plc (LON:PRTC) shares rose 0.7% on Friday . The company traded as high as GBX 139 and last traded at GBX 136. Approximately 263,559 shares traded hands during trading, a decline of 66% from the average daily volume of 777,319 shares. The stock had previously closed at GBX 135.

Analysts Set New Price Targets

Separately, Peel Hunt reiterated a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a report on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, PureTech Health currently has an average rating of “Buy” and a consensus price target of GBX 508.

PureTech Health Price Performance

The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The firm has a market capitalization of £328.69 million, a PE ratio of 8.00 and a beta of 1.02. The business’s 50 day moving average is GBX 125.38 and its two-hundred day moving average is GBX 128.62.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.